Why do pharma reps ignore CRM targeting lists, and what changes that?

Somewhere in the United States a physician writes a prescription, a pharmacy fills it, a patient starts therapy, and nobody at the manufacturer has ever spoken to that doctor.

Industry adoption of CRM targeting in pharma runs roughly twenty to thirty percent. At a specialty manufacturer of plasma-derived therapies, an agent that reads dispensing data continuously and attaches the reasoning to every recommended call reached adoption above ninety percent within six months, with adherence to high-priority targets above eighty-five percent.

Industry

Plasma-derived therapies

Who uses it

Pharma field force

What it does

Pharmaceutical field force targeting

Measured

Six months post-deployment, 2026

It happens because the prescription was written unbranded. The physician specified the therapy, not the manufacturer, and the pharmacy chose the product. From the manufacturer's side, a new prescriber has just appeared out of nowhere. They are, by any sensible reading, the single most promising person a rep could visit that week: a doctor who has already used the product once, with no relationship to lose and every reason to be receptive.

Historically, that doctor was invisible.

The company makes plasma-derived therapeutics for immune deficiencies and neurological conditions. There are roughly thirteen thousand relevant prescribers in the United States and a field force far smaller than that number. Which physician a rep visits on a given Tuesday is, in aggregate, one of the most consequential decisions the commercial organization makes.

Pharma has had a tool for this for thirty years. It is called the CRM, and it produces a targeting list. The industry's open secret is that reps largely ignore it. Typical adoption runs somewhere between twenty and thirty percent, and the reason is not laziness. A list that tells an experienced rep who to see without telling them why, built on data that was current last quarter, is worse than no list. It competes with the rep's own instinct and loses.

What the company built with InstaLILY started from that problem rather than from the technology. The system reads dispensing data continuously and hands the rep a prioritized set of calls with the reasoning attached. Prescribing volume is climbing at this clinic. This physician recently used the product for the first time and has never been contacted. This doctor was an early adopter of a different new therapy, which makes them unusually open to trying another. This account's orders dropped by about a quarter over sixty days and the volume appears to have moved to a competitor.

Then it does the thing that makes experienced commercial leaders sit up. It tells reps where to stop going.

Some physicians are already prescribing at close to the maximum share they ever will. Additional visits there produce nothing except the comfortable feeling of a warm call. Some clinics are committed to a different route of administration entirely, and converting them is a low-yield exercise dressed up as a pipeline. The system deprioritizes both, actively scoring them down rather than quietly leaving them off.

The whole thing runs inside the reps' existing workflow and CRM, with compliance constraints built into the logic rather than bolted on afterward, since which specialties can be approached about which products is not a matter of preference in this industry.

Six months in, the company's own reporting was unusual enough to state plainly. Adoption above ninety percent, against that twenty to thirty percent industry baseline. Adherence to high-priority targets above eighty-five percent. A new rep reaching productivity roughly three months faster than the previous norm. Two to three hours a week returned to every rep, which across a field team of a couple dozen is about a person and a half of capacity that did not exist before.

The adoption number is the one that matters, and not for the reason it first appears. Ninety percent does not mean the software is pleasant to use. It means the reps checked the recommendations against what they already knew, found them right often enough, and stopped arguing.

Which returns to the doctor nobody had met. Somebody goes to see her now, usually within weeks of that first prescription, while a patient is still early in treatment and the relationship is still available to build.

In this business the interval between a good decision and a patient starting the right therapy is measured in weeks, and it is made up almost entirely of which door a rep knocks on first.